Page 1 of 6
This document provides a short summary of this study for a general audience. You can
find more information in the scientific summary of the study. A link to the summary is
provided at the end of this document.
Study names
Short Title: A study to assess how well a combination of tafenoquine and
dihydroartemisinin-piperaquine works and how safe it is in patients with Plasmodium
vivax malaria.
Full Scientific Title: A double-blind, randomised, parallel group, placebo-controlled
superiority study to evaluate the efficacy and safety of tafenoquine (SB-252263,
WR238605) co-administered with dihydroartemisinin-piperaquine for the radical cure
of Plasmodium vivax malaria.
Study Number: 200894
Who sponsored this study?
GlaxoSmithKline (GSK)
GSK Clinical Support Help Desk
Website: clinicalsupporthd.gsk.com/contact.html
Email: GSKClinicalSupportHD@gsk.com
General information about the clinical study
When and where was this study done?
The study started in April 2018 and ended in August 2019. The study site was in
Indonesia.
What was the main objective of this study?
Malaria is a serious disease spread by mosquitoes infected with Plasmodium parasites.
When an infected mosquito bites a person, the parasites are passed from the mosquito
into the personâ€™s blood. Malaria can cause high fever, chills, other flu-like symptoms,
and low red blood cell count (anaemia).
Use of the data and information contained in this Document is unrestricted, provided that it may not
be used in applications by others for regulatory approval of a product. While not required, when using
these data, we ask that proper credit or attribution of GSK as the source of the data be given. GSK
disclaims liability for all uses of the data by users of this Document, to the fullest extent permitted by
applicable law. No trademark, patent, or regulatory/data exclusivity rights held by GSK are waived,
licensed or otherwise affected.